Metachromatic leukodystrophy (NORD)
00:00 / 00:00
Videos
Notes
Metachromatic leukodystrophy (NORD)
Information for patients and families
Glut1 Deficiency Foundation
Glut1 deficiency syndrome (Glut1 Deficiency Foundation)
Gorlin Syndrome Alliance
Gorlin syndrome (Gorlin Syndrome Alliance)
The National Organization for Rare Disorders (NORD)
Recurrent pericarditis (NORD)
Autoimmune polyglandular syndrome type 1 (NORD)
Opsoclonus myoclonus syndrome (NORD)
Thyroid eye disease (NORD)
Bile synthesis disorders (NORD)
Cyclic vomiting syndrome (NORD)
Eosinophilic esophagitis (NORD)
Short bowel syndrome (NORD)
Essential thrombocythemia (NORD)
Myelofibrosis (NORD)
Polycythemia vera (NORD)
Sickle cell disease (NORD)
Waldenstrom macroglobulinemia (NORD)
Warm autoimmune hemolytic anemia and cold agglutinin (NORD)
Congenital athymia (NORD)
Cytomegalovirus infection after transplant (NORD)
Post-transplant lymphoproliferative disorders (NORD)
Severe chronic neutropenia (NORD)
Adrenoleukodystrophy (NORD)
Alagille syndrome (NORD)
Aromatic L-amino acid decarboxylase deficiency (NORD)
Cerebrotendinous xanthomatosis (NORD)
Classical homocystinuria (NORD)
Congenital cytomegalovirus (NORD)
Cystinuria (NORD)
Fabry disease (NORD)
Gaucher disease (NORD)
Glycogen storage disease type II (NORD)
Metachromatic leukodystrophy (NORD)
Mucopolysaccharide storage disease type 1 (Hurler syndrome) (NORD)
Mucopolysaccharide storage disease type 2 (Hunter syndrome) (NORD)
Mycobacterium avium complex (NORD)
NGLY1 deficiency (NORD)
Niemann-Pick disease types A and B (NORD)
Phenylketonuria (NORD)
PIK3CA-related overgrowth spectrum (NORD)
Tay-Sachs disease (NORD)
Zellweger spectrum disorders (NORD)
Early infantile epileptic encephalopathy (NORD)
Opsoclonus myoclonus syndrome (NORD)
Spinocerebellar ataxia (NORD)
Narcolepsy (NORD)
Focal segmental glomerulosclerosis (NORD)
IgA nephropathy (NORD)
Pulmonary arterial hypertension (NORD)
The Primary School
ADHD: Information for patients and families (The Primary School)
Asthma: Information for patients and families (The Primary School)
Childhood nutrition and obesity: Information for patients and families (The Primary School)
Childhood oral health: Information for patients and families (The Primary School)
Food allergies and EpiPens: Information for patients and families (The Primary School)
Toxic stress: Information for patients and families (The Primary School)
Assessments
Metachromatic leukodystrophy (NORD)
Flashcards
0 / 10 complete
USMLE® Step 1 questions
0 / 2 complete
High Yield Notes
6 pages
Flashcards
Metachromatic leukodystrophy (NORD)
of complete
Questions
USMLE® Step 1 style questions USMLE
of complete
External References
First Aid
2022
2021
2020
2019
2018
2017
2016
Arylsulfatase A
metachromatic leukodystrophy p. 86
Ataxia
metachromatic leukodystrophy p. 86
Dementia
metachromatic leukodystrophy p. 86
Demyelination
metachromatic leukodystrophy p. 86
Metachromatic leukodystrophy p. 86
Transcript
Content Reviewers
Metachromatic leukodystrophy, or MLD, is a rare lysosomal storage disorder that results from mutations in the ARSA gene, which codes for arylsulfatase A - an enzyme that normally breaks down a fat called sulfatide.
Without this enzyme, sulfatide accumulates in neurons and myelin-producing cells like Schwann cells and oligodendrocytes, resulting in their degeneration.
MLD is an autosomal recessive disorder, which means that two mutated copies of the gene, one from each parent, are needed to develop the disease.
In rare cases, MLD can also be caused by mutations in the PSAP gene, which codes for saposin B, which is a protein that activates arylsulfatase A.
Without arylsulfatase A, cells cannot recycle sulfatides.
The sulfatide accumulates within cells of the nervous system like Schwann cells and oligodendrocytes, and aggregates to forms intracellular granules.
These sulfatide aggregates are called metachromatic since they appear differently colored than the cellular material when stained and seen under the microscope.
Sulfatide granules interferes with the cells’ ability to produce myelin, resulting in demyelination, or loss of myelin sheath, of the neurons.
The end result is impaired nerve impulse transmission.
Demyelination in MLD occurs both in the central as well as peripheral nervous system, resulting in a variety of symptoms.
Common symptoms include peripheral neuropathy, which is the loss of sensation in the extremities, diminished deep tendon reflexes, visual disturbances, difficulty in speaking, difficulty in walking, ataxia, behavior and personality changes, and seizures.
Now, there are three forms of MLD based on the age at onset of symptoms - late-infantile form, juvenile form, and adult form. In the late-infantile form, symptoms develop within the first three years of life, and include irritability and developmental delay.
In the juvenile form, symptoms usually develop between the age of 4 and adolescence, which is around 12- 14 years of age, and include behavioral changes and decreased ability in school.
In the adult form, symptoms usually develop after the age of 16, and include memory loss and psychosis.
For Institutions
Copyright © 2023 Elsevier, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Cookies are used by this site.
USMLE® is a joint program of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). COMLEX-USA® is a registered trademark of The National Board of Osteopathic Medical Examiners, Inc. NCLEX-RN® is a registered trademark of the National Council of State Boards of Nursing, Inc. Test names and other trademarks are the property of the respective trademark holders. None of the trademark holders are endorsed by nor affiliated with Osmosis or this website.
